Lupin Achieves a Major Milestone for its Phase 1 Clinical Stage MALT1 Inhibitor Programme

Lupin Limited announced the achievement of a key milestone for its novel MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor programme, which is being developed in collaboration with AbbVie Inc. to treat a variety of haematological cancers. Lupin received USD 25 million from AbbVie as part of the agreement for successfully initiating phase 1 clinical studies.

Lupin had previously received USD 30 million from AbbVie for meeting other programme milestones. In 2018, Lupin and AbbVie signed a licencing, development, and commercialization agreement for this novel oncology drug for the treatment of haematological cancers. Lupin's MALT1 inhibitor, which was developed as part of its oncology pipeline, had previously demonstrated pre-clinical activity as both a single agent and in combination.

"This accomplishment demonstrates our ability to successfully develop novel treatments for unmet needs." "We look forward to the continued success of this important treatment for patients with difficult-to-treat cancers," said Nilesh Gupta, Lupin's managing director. Lupin’s Novel Drug Discovery and Development (NDDD) team is focused on building a pipeline of highly differentiated and innovative new chemical entities in the oncology space.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.